Novel Vasodilator QLS-111 Shows Additive IOP Lowering with Latanoprost
Overview
QLS-111, a novel vasodilatory agent targeting distal outflow pathways, demonstrated an additional 3.2 to 3.6 mmHg intraocular pressure (IOP) reduction when added to latanoprost in the Apterix study. The agent has a favorable safety profile and is administered once daily in the evening.
Background
Glaucoma management often begins with topical IOP-lowering agents, but many patients require additional therapies to achieve target pressures. Current treatments include laser and surgical options, yet topical medications remain the mainstay. QLS-111 is a novel vasodilator designed to improve aqueous humor outflow distal to the trabecular meshwork and potentially enhance optic nerve head perfusion. Its preservative-free, isotonic, and pH-neutral formulation supports a good safety profile.
Data Highlights
| Parameter | Result |
|---|---|
| Additional IOP reduction on latanoprost | 3.2 to 3.6 mmHg |
| Dosing regimen | Once daily, PM |
| Formulation characteristics | Preservative-free, isotonic, pH neutral |
Key Findings
- QLS-111 acts as a vasodilator targeting the distal outflow system beyond the trabecular meshwork.
- In the Apterix study, QLS-111 added to latanoprost reduced IOP by approximately 3.2 to 3.6 mmHg.
- The optimal dosing is once daily in the evening (PM).
- The formulation is preservative-free, isotonic, and pH neutral, contributing to an excellent safety profile.
- QLS-111 may also improve optic nerve head perfusion, potentially benefiting glaucoma patients beyond IOP reduction.
- A fixed-dose combination of latanoprost and QLS-111 is under consideration to enhance patient adherence and outcomes.
Clinical Implications
QLS-111 offers a novel mechanism of action by vasodilating distal outflow pathways, providing an effective adjunct to latanoprost for additional IOP lowering. Its favorable safety profile and once-daily dosing may improve patient adherence and expand therapeutic options for glaucoma management. Clinicians should consider this agent as a promising addition to topical therapy regimens.
Conclusion
QLS-111 represents a promising new topical vasodilator that effectively lowers IOP when combined with latanoprost, addressing an unmet need for additional glaucoma therapies with a strong safety profile. Further development of fixed-dose combinations may enhance treatment convenience and efficacy.
References
- Wirostko BW, AGS 2026 -- Novel Vasodilator Targets Distal Outflow
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.